Navigation Links
Initiation of FLINT Announced by NIDDK: Study of Intercept Pharmaceuticals' Obeticholic Acid (INT-747) in NASH
Date:3/29/2011

NEW YORK, March 29, 2011 /PRNewswire/ -- Intercept Pharmaceuticals, Inc., has been informed by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health that patient enrollment has started in a new clinical trial in patients with nonalcoholic steatohepatitis (NASH), which will evaluate Intercept's first-in-class farnesoid X receptor (FXR) agonist obeticholic acid (OCA) as a novel therapy for NASH. The FXR Ligand NASH Treatment (FLINT) trial is a double blind, placebo controlled, multi-center clinical study that will evaluate the effects of OCA compared with placebo in adult NASH patients.

NASH is a more serious form of nonalcoholic fatty liver disease (NAFLD) and occurs in patients who drink little or no alcohol. The disease is believed to be caused by abnormal metabolism of fats and, although it is often associated with obesity and insulin resistance, it also occurs in lean individuals. NASH is associated with fibrosis (scarring) in the liver that may lead to cirrhosis, liver cancer and death, and the disease also carries an additional mortality risk due to heart disease. NASH is now the most common liver disease in the developed world, affecting at least 3-5% of the U.S. population and up to 50% of patients with morbid obesity.  There is currently no approved treatment for the disease.

FLINT will enroll 280 patients at the eight U.S. centers comprising the NIDDK-sponsored NASH Clinical Research Network.  The primary endpoint in the 72 week study will be determined by liver biopsy and is defined as an improvement in the NAFLD activity score with no worsening of liver fibrosis.  NIDDK is providing the majority of funding for the study and is partnering with Intercept under a cooperative research and development agreement (CRADA).

"It is a privilege to be collaborating with this group of leading NASH investigators and the NIDDK," commented David Shapiro, MD, Chief Medical O
'/>"/>

SOURCE Intercept Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Vion Pharmaceuticals Announces Initiation of a Phase I/II Trial of Cloretazine(R) (VNP40101M) in Combination with Temodar(R) in Adult Brain Tumors
2. Pharmacopeia Earns Milestone Payment From Schering-Plough on Initiation of Phase 1 Clinical Trials of Novel Therapeutic Candidate
3. Nastech Pharmaceutical Company Announces Initiation of Phase 2 Clinical Trial for Insulin Nasal Spray to Treat Diabetes
4. Nastech Pharmaceutical Company Announces Initiation of Phase 2 Clinical Trial for PYY3-36 Nasal Spray to Treat Obesity
5. Isis Earns $5 Million Milestone Payment From Ortho-McNeil, Inc. for Initiation of Phase 1 Study of ISIS 325568
6. Palatin Technologies, Inc. Reports Initiation of Human Trials for the Treatment of Congestive Heart Failure
7. Epiphany Biosciences Reports Initiation and Enrollment in Valomaciclovir Study for Shingles
8. Retrospective Analysis Finds That Initiation of Insulin Glargine in Patients With Type 2 Diabetes was Associated With a Lower Incidence Rate of Myocardial Infarction as Compared With NPH Insulin
9. Synvista Therapeutics Announces Initiation of Phase 2 Study With Alagebrium for Chronic Heart Failure
10. Vion Pharmaceuticals Announces Initiation of Clinical Trial of Cloretazine(R) (VNP40101M) in Combination with Stem Cell Transplantation
11. Rigel Announces Initiation of Phase 1 Clinical Trial of R343 for Allergic Asthma by its Partner Pfizer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... 29, 2014  Novation, a VHA and UHC ... breakthrough interactive features that automate key health care ... Children,s Hospital Association.  The new ... umbrella – Value Analysis, Item Master and Formulary ... address the most critical challenges brought on by ...
(Date:7/29/2014)... July 29, 2014  The BioFusionary Corporation, Inc. ... a proprietary electromagnetic induction platform with aesthetic and ... agreement under which TBC will merge with ... in an all-stock transaction. Upon completion ... on the Australian Stock Exchange under the code ...
(Date:7/29/2014)... -- Encision Inc. (OTCQB:ECIA), a medical device company owning patented ... minimally invasive surgery, today announced financial results for its ... The Company posted quarterly net revenue of $2.476 ... or $(0.02) per share. These results compare to net ... $311 thousand, or $(0.04) per share, in the year-ago ...
Breaking Medicine Technology:Breakthrough Novation Applications Empower Children's Hospital Association Members to Lower Costs, Increase Quality 2Breakthrough Novation Applications Empower Children's Hospital Association Members to Lower Costs, Increase Quality 3Breakthrough Novation Applications Empower Children's Hospital Association Members to Lower Costs, Increase Quality 4Breakthrough Novation Applications Empower Children's Hospital Association Members to Lower Costs, Increase Quality 5The BioFusionary Corporation, Inc. Announces Intent To Complete Reverse Takeover Of Australia-Based Continuation Investments Limited 2The BioFusionary Corporation, Inc. Announces Intent To Complete Reverse Takeover Of Australia-Based Continuation Investments Limited 3Encision Reports First Quarter Fiscal Year 2015 Results 2Encision Reports First Quarter Fiscal Year 2015 Results 3Encision Reports First Quarter Fiscal Year 2015 Results 4
... , , , SAN FRANCISCO, Dec. 14 ... its promised announcement about health hazards of bisphenol A (BPA), ... harm and other illnesses, in time for Christmas. , ... Natural Resources Defense Council : "Just as you rely on ...
... ,Dec. 14 /PRNewswire-FirstCall/ -- VION PHARMACEUTICALS, INC. ... received a complete response letter from the U.S. Food ... Application ("NDA") for Onrigin(TM) (laromustine) injection submitted in February ... approve the Company,s NDA in its present form and ...
Cached Medicine Technology:Toxic Chemical bisphenol A Still Not Banned By FDA; Schumer, Gillibrand Call for Ban; Govt Official Warns Public 2Vion Pharmaceuticals Receives Complete Response Letter for Onrigin(TM) From The U.S. Food And Drug Administration 2Vion Pharmaceuticals Receives Complete Response Letter for Onrigin(TM) From The U.S. Food And Drug Administration 3
(Date:7/29/2014)... Researchers who discovered a group of new materials ... prestigious research award worth a combined 2m to ... polymers could lead to a significant reduction in ... improve the health care of hospital patients across ... Surfaces in the School of Pharmacy and Paul ...
(Date:7/29/2014)... LA JOLLA, Calif. (PRWEB) July 29, 2014 ... provides a comprehensive overview of the hepatitis C (hep ... and the potential of these treatments to reduce human ... broader understanding of the impact of hep C, while ... to a new era of treatment. CHI is a ...
(Date:7/29/2014)... Lake City, UT (PRWEB) July 29, 2014 ... how Activz produce powders can help parents add nutrition ... Magazine article “Little Bites – Key market drivers in ... Whole-Food Nutrition, is pleased to announce the interview ... benefits of adding the Activz organic vegetable and fruit ...
(Date:7/29/2014)... Cold Spring Harbor, NY -- Researchers at Cold Spring Harbor ... most important tumor-suppressing protein. Called p53, this protein has been ... the fore when healthy cells sense damage to their DNA ... intense exposure to the sun,s UV rays. If the ... preprogrammed cell-death, or apoptosis. Mutant versions of p53 that ...
(Date:7/29/2014)... (PRWEB) July 29, 2014 July 29, 2014 ... home care, is proud to announce that it is a ... inspiring online video segments; Silverado Through a Child's Eye ... , In Silverado Through a Child's Eye , ... her mom at Silverado Beverly Place, a memory care community ...
Breaking Medicine News(10 mins):Health News:Bacteria resistant materials -- £2m to get the 'inside' story 2Health News:Bacteria resistant materials -- £2m to get the 'inside' story 3Health News:CHI Releases Report Highlighting Public Impact of Hepatitis C, Opportunities for Action in US 2Health News:CHI Releases Report Highlighting Public Impact of Hepatitis C, Opportunities for Action in US 3Health News:CHI Releases Report Highlighting Public Impact of Hepatitis C, Opportunities for Action in US 4Health News:Activz Organic Fruit and Vegetable Produce Powders and Founder Frank Davis Mentioned in WholeFoods Magazine Article 2Health News:Activz Organic Fruit and Vegetable Produce Powders and Founder Frank Davis Mentioned in WholeFoods Magazine Article 3Health News:Research may explain how foremost anticancer 'guardian' protein learned to switch sides 2Health News:Silverado Selected a Winner in the 35th Annual Telly Awards for Producing Inspiring Online Video Content 2
... A major study published in the November,2007 edition of ... women who completed a study using the Brava System ... full breast size. This key,finding was based on a ... Schlenz, M.D. and Alexandra Kaider, M. Sc. The study ...
... NEW YORK, Oct. 29 The Consumer-Purchaser,Disclosure Project ... employer,organizations working to ensure that all Americans have ... applauds today,s agreement,between the Attorney General of New ... physician performance. This important agreement will,allow physician performance ...
... reminder program, TORONTO, Oct. 29 /PRNewswire/ - Organon ... free telephone-based reminder program designed to,help women remember their ... million women (Stat. Can., 2001) take oral,contraceptives everyday and ... take it at least once. Although the pill is ...
... Key Element To An Effective, Hygiene Protocol. ... WASHINGTON, Oct. 29 The recent outbreak ... as an important,reminder of the importance of routine, ... large number of people constantly live,work or play. ...
... heart despite symptom relief, experts say , , MONDAY, Oct. ... than they did 40 years ago, but not if they ... Mayo Clinic. , "When you look at persons with rheumatoid ... over the last several decades of improved survival the rest ...
... chronic tendinosis of the Achilles tendon can experience a ... of a dextrose solution, according to a recent study ... BC. , Chronic tendinosis is a common overuse injury ... affect many tendons throughout the body, said Norman J. ...
Cached Medicine News:Health News:Newly Published Study in Leading Medical Journal Further Confirms the Brava System's Non-Surgical Breast Enhancement Effectiveness 2Health News:Consumers, Health Care Purchasers Applaud Agreement On Physician Performance Reporting 2Health News:Consumers, Health Care Purchasers Applaud Agreement On Physician Performance Reporting 3Health News:Consumers, Health Care Purchasers Applaud Agreement On Physician Performance Reporting 4Health News:Canada leads the way in contraceptive compliance 2Health News:Canada leads the way in contraceptive compliance 3Health News:Spate of Staph Infections Highlight the Need for Thorough, Consistent Cleaning Regimen at Home, at School and at Work 2Health News:Rheumatoid Arthritis Death Rate Unchanged 2Health News:Rheumatoid Arthritis Death Rate Unchanged 3Health News:Ultrasound-guided injections help ease chronic Achilles tendon pain 2
... ACMI™ USA Elite System Rotating Continuous Flow ... the urologist to rotate the working element ... of the sheaths. The result no ... tangled tubing due to rotating flow ports, ...
... PC-based ECG device that can be ... an innovative software. The system enables ... using a standard 12-lead setup that ... software includes two applications: Rest ECG ...
Used for traversing and exploring urethral strictures. The malleable tip can be shaped to desired configuration. The proximal end is threaded to attach to standard followers. Supplied sterile in peel...
The removable inflation adapter allows the ureteroscope to be removed after the catheter is in place. Supplied sterile in peel-open packages. Intended for one-time use....
Medicine Products: